Thyroid:自噬与Graves眼病的发生发展相关

2015-04-24 沐晴 译 MedSci原创

关于Graves眼病(GO)的发病机制目前尚未完全清楚。比较可能的机制是眼肌周围的成纤维细胞(perimysial fibroblast)、眼球后脂肪组织的脂肪细胞和成纤维细胞的细胞膜上有促甲状腺激素受体(TSH-R)。T细胞作用于上述有TSH-R的细胞,分泌细胞因子,刺激这些细胞增生,分泌糖胺聚糖(glycosaminoglycan)和表达主要组织相容性复合物(MHC class Ⅱ)抗原(HL

关于Graves眼病(GO)的发病机制目前尚未完全清楚。比较可能的机制是眼肌周围的成纤维细胞(perimysial fibroblast)、眼球后脂肪组织的脂肪细胞和成纤维细胞的细胞膜上有促甲状腺激素受体(TSH-R)。T细胞作用于上述有TSH-R的细胞,分泌细胞因子,刺激这些细胞增生,分泌糖胺聚糖(glycosaminoglycan)和表达主要组织相容性复合物(MHC class Ⅱ)抗原(HLA-DR)。研究表明,自噬与脂肪生成相关,但是关于自噬对GO发生与进展的影响知之甚少。近来,来自韩国的研究者,就检测了自噬在GO发病机制中的作用。
     

研究者分别对来自GO患者组和正常对照组的眼眶脂肪组织/结缔组织,及离体的眼眶成纤维细胞进行分析。使用含/或不含H2O2的介质诱导脂肪组织生成,使用洛霉素A和Atg5-为靶点的shRNA调控自噬水平。在电子显微镜下观察自噬溶酶体的数目。使用RT-PCR和/或Western blot分析检测自噬相关基因的表达和脂质生成相关基因的转录因子水平。油红O染色方法用来检测脂滴的形成。
    
研究结果显示,与非GO细胞相比,自噬体在GO细胞中数目更多。自噬相关基因在GO组织中的表达水平,与对照组(非GO组织)相比,显著升高。IL-1β增加了GO细胞中LC3-II,p62,和Atg7蛋白的水平。在脂质形成的第4天,自噬溶酶体聚集增多,但是在脂质形成的第10天,自噬溶酶体数目减少。LC3和p62蛋白的表达在细胞发生分化的前48小时是升高的,但在第4到10天之内,逐渐降低。洛霉素A1治疗和通过shRNA将Atg敲除可以抑制脂滴形成和脂质生成因子的表达。

最终,研究者认为,与非GO组织和细胞相比,GO组织和细胞中自噬水平升高的,提示自噬可能参与GO的发病。调节GO自噬水平有望成为一种GO的治疗方法。

原始出处:

Yoon JS, Lee HJ, Chae MK, Autophagy is Involved in the Initiation and Progression of Graves' Orbitopathy. Thyroid. 2015 Apr;25(4):445-54. doi: 10.1089/thy.2014.0300

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2030716, encodeId=252c2030e16a7, content=<a href='/topic/show?id=71353e8964f' target=_blank style='color:#2F92EE;'>#发生发展#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37896, encryptionId=71353e8964f, topicName=发生发展)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=346311, createdName=wgsun, createdTime=Fri Feb 12 12:31:00 CST 2016, time=2016-02-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2039586, encodeId=6fbf203958664, content=<a href='/topic/show?id=7ae88244a6' target=_blank style='color:#2F92EE;'>#Graves#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8244, encryptionId=7ae88244a6, topicName=Graves)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f49517, createdName=xinmeili, createdTime=Thu May 14 12:31:00 CST 2015, time=2015-05-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1515312, encodeId=02ca1515312fa, content=<a href='/topic/show?id=b3e18249d3' target=_blank style='color:#2F92EE;'>#Graves眼病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8249, encryptionId=b3e18249d3, topicName=Graves眼病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3e2210763438, createdName=若水126, createdTime=Sun Apr 26 06:31:00 CST 2015, time=2015-04-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1540485, encodeId=01d8154048531, content=<a href='/topic/show?id=fbbce2786cc' target=_blank style='color:#2F92EE;'>#眼病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72786, encryptionId=fbbce2786cc, topicName=眼病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b85c13256921, createdName=pps20023, createdTime=Sun Apr 26 06:31:00 CST 2015, time=2015-04-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=21954, encodeId=62542195493, content=有可能, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=cspcsp, createdTime=Sat Apr 25 12:31:00 CST 2015, time=2015-04-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=21955, encodeId=91ac219553b, content=实用, beContent=null, objectType=article, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=cspcsp, createdTime=Sat Apr 25 12:31:00 CST 2015, time=2015-04-25, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=2030716, encodeId=252c2030e16a7, content=<a href='/topic/show?id=71353e8964f' target=_blank style='color:#2F92EE;'>#发生发展#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37896, encryptionId=71353e8964f, topicName=发生发展)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=346311, createdName=wgsun, createdTime=Fri Feb 12 12:31:00 CST 2016, time=2016-02-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2039586, encodeId=6fbf203958664, content=<a href='/topic/show?id=7ae88244a6' target=_blank style='color:#2F92EE;'>#Graves#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8244, encryptionId=7ae88244a6, topicName=Graves)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f49517, createdName=xinmeili, createdTime=Thu May 14 12:31:00 CST 2015, time=2015-05-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1515312, encodeId=02ca1515312fa, content=<a href='/topic/show?id=b3e18249d3' target=_blank style='color:#2F92EE;'>#Graves眼病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8249, encryptionId=b3e18249d3, topicName=Graves眼病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3e2210763438, createdName=若水126, createdTime=Sun Apr 26 06:31:00 CST 2015, time=2015-04-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1540485, encodeId=01d8154048531, content=<a href='/topic/show?id=fbbce2786cc' target=_blank style='color:#2F92EE;'>#眼病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72786, encryptionId=fbbce2786cc, topicName=眼病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b85c13256921, createdName=pps20023, createdTime=Sun Apr 26 06:31:00 CST 2015, time=2015-04-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=21954, encodeId=62542195493, content=有可能, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=cspcsp, createdTime=Sat Apr 25 12:31:00 CST 2015, time=2015-04-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=21955, encodeId=91ac219553b, content=实用, beContent=null, objectType=article, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=cspcsp, createdTime=Sat Apr 25 12:31:00 CST 2015, time=2015-04-25, status=1, ipAttribution=)]
    2015-05-14 xinmeili
  3. [GetPortalCommentsPageByObjectIdResponse(id=2030716, encodeId=252c2030e16a7, content=<a href='/topic/show?id=71353e8964f' target=_blank style='color:#2F92EE;'>#发生发展#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37896, encryptionId=71353e8964f, topicName=发生发展)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=346311, createdName=wgsun, createdTime=Fri Feb 12 12:31:00 CST 2016, time=2016-02-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2039586, encodeId=6fbf203958664, content=<a href='/topic/show?id=7ae88244a6' target=_blank style='color:#2F92EE;'>#Graves#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8244, encryptionId=7ae88244a6, topicName=Graves)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f49517, createdName=xinmeili, createdTime=Thu May 14 12:31:00 CST 2015, time=2015-05-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1515312, encodeId=02ca1515312fa, content=<a href='/topic/show?id=b3e18249d3' target=_blank style='color:#2F92EE;'>#Graves眼病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8249, encryptionId=b3e18249d3, topicName=Graves眼病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3e2210763438, createdName=若水126, createdTime=Sun Apr 26 06:31:00 CST 2015, time=2015-04-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1540485, encodeId=01d8154048531, content=<a href='/topic/show?id=fbbce2786cc' target=_blank style='color:#2F92EE;'>#眼病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72786, encryptionId=fbbce2786cc, topicName=眼病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b85c13256921, createdName=pps20023, createdTime=Sun Apr 26 06:31:00 CST 2015, time=2015-04-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=21954, encodeId=62542195493, content=有可能, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=cspcsp, createdTime=Sat Apr 25 12:31:00 CST 2015, time=2015-04-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=21955, encodeId=91ac219553b, content=实用, beContent=null, objectType=article, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=cspcsp, createdTime=Sat Apr 25 12:31:00 CST 2015, time=2015-04-25, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=2030716, encodeId=252c2030e16a7, content=<a href='/topic/show?id=71353e8964f' target=_blank style='color:#2F92EE;'>#发生发展#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37896, encryptionId=71353e8964f, topicName=发生发展)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=346311, createdName=wgsun, createdTime=Fri Feb 12 12:31:00 CST 2016, time=2016-02-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2039586, encodeId=6fbf203958664, content=<a href='/topic/show?id=7ae88244a6' target=_blank style='color:#2F92EE;'>#Graves#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8244, encryptionId=7ae88244a6, topicName=Graves)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f49517, createdName=xinmeili, createdTime=Thu May 14 12:31:00 CST 2015, time=2015-05-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1515312, encodeId=02ca1515312fa, content=<a href='/topic/show?id=b3e18249d3' target=_blank style='color:#2F92EE;'>#Graves眼病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8249, encryptionId=b3e18249d3, topicName=Graves眼病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3e2210763438, createdName=若水126, createdTime=Sun Apr 26 06:31:00 CST 2015, time=2015-04-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1540485, encodeId=01d8154048531, content=<a href='/topic/show?id=fbbce2786cc' target=_blank style='color:#2F92EE;'>#眼病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72786, encryptionId=fbbce2786cc, topicName=眼病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b85c13256921, createdName=pps20023, createdTime=Sun Apr 26 06:31:00 CST 2015, time=2015-04-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=21954, encodeId=62542195493, content=有可能, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=cspcsp, createdTime=Sat Apr 25 12:31:00 CST 2015, time=2015-04-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=21955, encodeId=91ac219553b, content=实用, beContent=null, objectType=article, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=cspcsp, createdTime=Sat Apr 25 12:31:00 CST 2015, time=2015-04-25, status=1, ipAttribution=)]
    2015-04-26 pps20023
  5. [GetPortalCommentsPageByObjectIdResponse(id=2030716, encodeId=252c2030e16a7, content=<a href='/topic/show?id=71353e8964f' target=_blank style='color:#2F92EE;'>#发生发展#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37896, encryptionId=71353e8964f, topicName=发生发展)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=346311, createdName=wgsun, createdTime=Fri Feb 12 12:31:00 CST 2016, time=2016-02-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2039586, encodeId=6fbf203958664, content=<a href='/topic/show?id=7ae88244a6' target=_blank style='color:#2F92EE;'>#Graves#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8244, encryptionId=7ae88244a6, topicName=Graves)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f49517, createdName=xinmeili, createdTime=Thu May 14 12:31:00 CST 2015, time=2015-05-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1515312, encodeId=02ca1515312fa, content=<a href='/topic/show?id=b3e18249d3' target=_blank style='color:#2F92EE;'>#Graves眼病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8249, encryptionId=b3e18249d3, topicName=Graves眼病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3e2210763438, createdName=若水126, createdTime=Sun Apr 26 06:31:00 CST 2015, time=2015-04-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1540485, encodeId=01d8154048531, content=<a href='/topic/show?id=fbbce2786cc' target=_blank style='color:#2F92EE;'>#眼病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72786, encryptionId=fbbce2786cc, topicName=眼病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b85c13256921, createdName=pps20023, createdTime=Sun Apr 26 06:31:00 CST 2015, time=2015-04-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=21954, encodeId=62542195493, content=有可能, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=cspcsp, createdTime=Sat Apr 25 12:31:00 CST 2015, time=2015-04-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=21955, encodeId=91ac219553b, content=实用, beContent=null, objectType=article, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=cspcsp, createdTime=Sat Apr 25 12:31:00 CST 2015, time=2015-04-25, status=1, ipAttribution=)]
    2015-04-25 cspcsp

    有可能

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=2030716, encodeId=252c2030e16a7, content=<a href='/topic/show?id=71353e8964f' target=_blank style='color:#2F92EE;'>#发生发展#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37896, encryptionId=71353e8964f, topicName=发生发展)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=346311, createdName=wgsun, createdTime=Fri Feb 12 12:31:00 CST 2016, time=2016-02-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2039586, encodeId=6fbf203958664, content=<a href='/topic/show?id=7ae88244a6' target=_blank style='color:#2F92EE;'>#Graves#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8244, encryptionId=7ae88244a6, topicName=Graves)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f49517, createdName=xinmeili, createdTime=Thu May 14 12:31:00 CST 2015, time=2015-05-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1515312, encodeId=02ca1515312fa, content=<a href='/topic/show?id=b3e18249d3' target=_blank style='color:#2F92EE;'>#Graves眼病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8249, encryptionId=b3e18249d3, topicName=Graves眼病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3e2210763438, createdName=若水126, createdTime=Sun Apr 26 06:31:00 CST 2015, time=2015-04-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1540485, encodeId=01d8154048531, content=<a href='/topic/show?id=fbbce2786cc' target=_blank style='color:#2F92EE;'>#眼病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72786, encryptionId=fbbce2786cc, topicName=眼病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b85c13256921, createdName=pps20023, createdTime=Sun Apr 26 06:31:00 CST 2015, time=2015-04-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=21954, encodeId=62542195493, content=有可能, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=cspcsp, createdTime=Sat Apr 25 12:31:00 CST 2015, time=2015-04-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=21955, encodeId=91ac219553b, content=实用, beContent=null, objectType=article, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=cspcsp, createdTime=Sat Apr 25 12:31:00 CST 2015, time=2015-04-25, status=1, ipAttribution=)]
    2015-04-25 cspcsp

    实用

    0

相关资讯

Oncotarget:PTPRO介导的自噬可以阻止脂肪肝和肝细胞癌发生

以往研究表明细胞自噬在非酒精性脂肪肝(NASH)和肝细胞癌(HCC)的进展中起非常重要的作用。蛋白酪氨酸磷酸酶受体O (PTPRO)是最近发现的肿瘤抑制因子,但是关于它在NASH的研究很少。近来有研究,证明PTPRO介导的细胞自噬与胰岛素抵抗、脂代谢、肝癌发生相关。 研究者选取同源的野生型小鼠(对照组)和ptpro−/−小鼠(试验组)作为实验对象,首先使用二乙基亚硝胺造NAS

综述:细胞自噬与凋亡的交互作用

细胞自噬又称Ⅱ型程序性细胞死亡,参与了多种疾病的发生和发展。自噬与凋亡之间存在着复杂的交互调控——二者能被多种应激刺激共同激活、共享多个调节分子,甚至互相协调转化等。全面深入研究自噬与凋亡之间的交互作用机制,将为肿瘤等疾病的认知及治疗带来突破性进展。细胞死亡是被周密调控的复杂过程。凋亡,作为第一个被认定的程序性细胞死亡程序(programmed cell death, PCD),其作用及

自噬--细胞的守护神(上)

tor/uploadfile/201402/20140225094530393.jpg" height="235" width="562"> More effects of autophagy     Image source Beyond its cell-autonomous action, autophagy can reduce age-rela

Cell Rep:自噬令垂死的癌细胞复活

凋亡能够从内部撕碎癌细胞,但最近科学家们发现,这些在死亡线上挣扎的癌细胞能够通过增强自噬而复活,这项研究发表在Cell旗下Cell Reports杂志上。文章向人们展示了,癌细胞从凋亡中幸存的分子机制,而这一机制有助于进一步理解癌细胞对化疗药物所产生的抵抗。“这项研究带给我们的启示是,抑制自噬有助于减少上述情况的发生,帮助化疗药物彻底杀死癌细胞,”文章的资深作者,科罗拉多大学癌症中心的Andrew

Cell:EGFR在自噬发生过程中的激酶非依赖性作用

近日,国际生物学顶尖期刊cell 刊登了来自麦迪逊威斯康星大学Richard A. Anderson研究小组的一项最新研究成果,他们通过研究发现非激活型EGFR能够通过与癌蛋白LAPTM4B相互作用参与自噬起始过程,而这一过程并不依赖于EGFR的激酶活性。这条信号通路可能对于控制肿瘤代谢,在代谢应激情况下促进肿瘤细胞存活具有重要意义。   研究人员指出,自噬是细胞在营养缺乏情

Mol Cell:中国科学家发现蛋白修饰与自噬起始新关系

该文章发现在细胞核内,LC3能够与Sirt1发生相互作用,在K49和K51位置发生去乙酰化,改变LC3在细胞内的分布。这项成果为进一步研究蛋白质修饰与蛋白在细胞内分布的关系提供了重要启示